



IFW

PATENT
ATTORNEY DOCKET NO. 50206/012002

Certificate of Mailing: Date of Deposit: July 8, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sean L. Avery

Printed name of person mailing correspondence

[Signature]
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nicholas P. Barker et al. Art Unit: 1645
Serial No.: 10/698,572 Examiner: P. A. Duffy
Filed: October 31, 2003 Customer No.: 21559
Title: TREFOIL DOMAIN-CONTAINING POLYPEPTIDES AND USES
THEREOF

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents. Copies of search reports from corresponding European and international applications are also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the

merits.


If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,


Date:

8 July 2005



Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50206/012002
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/698,572
				Applicant	Barker et al.
				Filing Date	October 31, 2003
				Group	1645
				IDS Filed	July 8, 2005
(37 C.F.R. §1.98(b))				Customer No.	21559

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Issue/ Publication Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	4,370,317	01/25/83	Jorgensen et al.			
	5,830,706	11/03/98	Mascarenhas et al.			
	6,063,755	05/16/00	Podolsky			
	6,426,404	07/30/02	Podolsky			
	2002-0052483 A1	05/02/02	Podolsky			
	2002-0187487 A1	12/12/02	Goldenring et al.			
FOREIGN PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 92/14837	09/03/92	WIPO			
	WO 94/17102	08/04/1994	WIPO			
	WO 96/06861	03/07/96	WIPO			
	WO 97/38712	10/23/97	WIPO			
	WO 99/18927	04/22/99	WIPO			
	WO 01/02570 A1	01/11/01	WIPO			
	WO 02/46226	06/13/02	WIPO			
	WO 02/085402 A	10/31/02	WIPO			
	FR 2769502	04/16/99	France			Yes (abstract from WO 99/18927)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed Customer No.	50206/012002 10/698,572 Barker et al. October 31, 2003 1645 July 8, 2005 21559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. §1.98(b))			

	Amorim et al., "Microparticles for delivering therapeutic peptides and proteing to the lumen of small intestine," <i>European J. Pharmaceutics and Biopharmaceutics</i> 52:39-44 (2001).
	Babyatsky et al., "Trefoil peptides protect against ethanol and indomethacin induced gastric injury in rats," <i>Gastroenterology</i> 106:A43 (1994).
	Babyatsky et al., "Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats" <i>Gastroenterology</i> 110:489-497 (1996).
	Beers, "The Merk Manual of Diagnosis and Therapy, Seventeenth Edition" pages 556-568, 1044-1050 and 1110-1113 (1999).
	Graness et al., "Protein kinase C and ERK activation are required for TFF-peptide-stimulated bronchial epithelial cell migration and tumor necrosis factor-alpha-induced interleukin-6 (IL-6) and IL-8 secretion," <i>J. Biol. Chem.</i> 277:18440-18446 (2002).
	Hauser et al., "hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus" <i>Proc. Natl. Acad. Sci. USA</i> 90:6961-6965 (1993).
	Kindon et al., "Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein" <i>Gastroenterology</i> 109:516-523 (1995).
	Kjellev et al., "Effect of systemically administered TFF3 on murine experimental colitis," <i>IV TFF Conference, Strasbourg, France</i> (Abstract/Poster) (December 2-4, 2004).
	Lefebvre et al., "The mouse one P-Domain (pS2) and two P-Domain (mSP) genes exhibit distinct patterns of expression," <i>J. Cell Biol.</i> 122:191-198 (1993).
	Mashimo et al., "Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor" <i>Science</i> 274:262-265 (1996).
	McKenzie et al., "Topical and intravenous administration of trefoil factors protect the gastric mucosa from ethanol-induced injury in the rat," <i>Aliment Pharmacol. Ther.</i> 14:1033-1040 (2000).
	Modlin et al., "Trefoil Peptides: Mitogens, Motogens, or Mirages?" <i>J. Clin. Gastroenterol.</i> 25(Suppl. 1):S94-S100 (1997).
	Oertel et al., "Trefoil factor family -- peptides promote migration of human bronchial epithelial cells" <i>Am. J. Respir. Cell Mol. Biol.</i> 25:418-424 (2001).
	Podolsky et al., "Identification of human intestinal trefoil factor," <i>J. Biol. Chem.</i> 268:6694-6702 (1993).
	Poulsen et al., "Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat," <i>Gut</i> 45:516-522 (1999).
	Wang et al., "Effect of antibody against integrin $\alpha 4$ on bleomycin-induced pulmonary fibrosis in mice," <i>Biochem. Pharmacol.</i> 60:1949-1958 (2000).
	Wiede et al., "Synthesis and localization of the mucin-associated TFF-peptides in the human uterus," <i>Cell Tissue Res.</i> 303:109-115 (2001).
	International Search Report mailed July 24, 1997 (PCT/US97/06004).
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50206/012002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/698,572
		Applicant	Barker et al.
		Filing Date	October 31, 2003
		Group	1645
		IDS Filed	July 8, 2005
(37 C.F.R. §1.98(b))		Customer No.	21559

	International Search Report mailed September 11, 2002 (PCT/US02/12891).
	International Search Report mailed March 28, 2003 (PCT/US02/31998).
	International Search Report mailed May 27, 2003 (PCT/US02/38258).
	International Search Report mailed October 20, 2003 (PCT/US03/09195).
	Communication and Supplementary European Search Report mailed June 1, 2004 (EP 02 76 4324).
	Communication and Supplementary European Search Report mailed July 5, 2004 (EP 97 92 1148).
	International Search Report mailed October 8, 2004 (PCT/US02/28339).
	Communication and Supplementary European Search Report mailed January 25, 2005 (EP 02 78 6828).
	Communication and Supplementary European Search Report mailed April 15, 2005 (EP 02 80 0937).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	